Please enable JS

Visible, proven results

Trinov, proven efficacy

Home / Trinov Programme / Clinical trials
Clinical studies confirm results after 6 months of treatment*

The male and female subjects taking part in a clinical study on Trinov hair-loss lotion have confirmed that daily application of the product for 6 months leads to a significant reduction in hair loss and confirmed that hair becomes stronger, healthier and fuller-bodied. The same subjects also reported that the lotion is readily absorbed and does not alter the condition of the scalp, whilst giving it a pleasant scent.

Study subjects
The efficacy of TRINOV hair-loss lotion was tested by treating two groups of healthy volunteers: 30 men of between 18 and 55 years of age and 30 women of between 30 and 60 years of age. The clinical study conducted to evaluate the efficacy of Trinov took place at ISPE srl (Institute of Skin and Product Evaluation) in compliance with the principles set forth in the Declaration of Helsinki and in accordance with GCP (good clinical practice) and GLP (good laboratory practice) standards.
The study included subjects with a hair-loss pattern typical of androgenetic alopecia, meeting the criteria for a stage of between 2 and 4 on the universally-recognised Norwood-Hamilton scale (Norwood et al., 1975) for the men and stage I or II on the Ludwig hair loss scale (Ludwig et al., 1977) for the women.
The treatment administered
The subjects were asked to apply 1 mL of TRINOV Hair-loss lotion for Men or TRINOV Hair-loss Lotion for Women every day, to the area of the scalp subject to the greatest shedding or hair loss, before spreading it over the entire surface of the scalp by massaging gently to favour absorption.
After 1, 3 and 6 months of use of the lotion, the volunteers were examined in order to evaluate a number of different parameters.
The parameters evaluated
  1. Total number of hairs and percentage of hairs in the anagen and telogen phases in the area of scalp subject to greatest shedding. This measurement was taken by acquiring special images, known as phototrichograms, which were used to measure the percentage of hairs in the anagen and telogen phases using an epiluminescence microscope (Tricoscan).
  2. Hair resistance to traction. This measurement was taken by pulling on locks of hair in three separate areas of the scalp (known as the pull test). The number of hairs removed was used to assign a score (0: >6 hairs; 1: 6-4 hairs; 2: 3-1 hairs; 3: no hairs removed).
  3. Number of hairs shed during washing. During study visits, the subjects’ hair was washed and the shed hair was collected after washing using special gauzes (wash test).
  4. Qualitative evaluation of the lotion’s tolerability by the investigator (dermatologist) in relation to the presence of itch, burning sensation, dandruff, seborrhoea and degree of any erythema present on the scalp.
  5. After 6 months of application, the volunteers were asked to answer a series of questions in a questionnaire to express an opinion on the tolerability and efficacy of Trinov, as well as its pleasantness.
The results obtained
The data collected in this study showed that, after six months of use of TRINOV Hair-loss Lotion, there was an increase in the total number of hairs in 63.3% of men and almost all (89.7%) of the female subjects treated.
A gradual increase was recorded in the percentage of hairs in anagen phase (this result was significant after three months of treatment in men and from the first month in women), which corresponded with a gradual decrease in the number of hairs in telogen phase. The results obtained with Trinov translated into thicker hair growth on the scalp in both sexes.
In addition, after using these lotions, the hair became more resistant (from the first month in women and after three months in men) and a significant decrease was seen in the number of hairs lost after washing from the first month of treatment in both cases (wash test).
*”A liposome-based formulation containing equol, dihomo-γ-linolenic acid and propionyl-L-carnitine to prevent and treat hair loss: A prospective investigation” G.Brotzu, A.M.Fadda, M.L.Manca, T.Manca, F.Marongiu, M.Campisi, F.Consolaro; Dermatologic Therapy, Ott.2018
img

Results of the study regarding the percentage of hairs in anagen phase (left) and telogen phase (right) in men (above, blue) and women (below, pink). The improvement is significant from T3 in men and from T1 in women.*
*”A liposome-based formulation containing equol, dihomo-γ-linolenic acid and propionyl-L-carnitine to prevent and treat hair loss: A prospective investigation” G.Brotzu, A.M.Fadda, M.L.Manca, T.Manca, F.Marongiu, M.Campisi, F.Consolaro; Dermatologic Therapy, Ott.2018

img

Two representative cases of one male volunteer and one female volunteer who used the lotion for 6 months (a, c: before use of the treatment; b, d: after 6 months’ use of the treatment).*
*”A liposome-based formulation containing equol, dihomo-γ-linolenic acid and propionyl-L-carnitine to prevent and treat hair loss: A prospective investigation” G.Brotzu, A.M.Fadda, M.L.Manca, T.Manca, F.Marongiu, M.Campisi, F.Consolaro; Dermatologic Therapy, Ott.2018

img

Percentage of male volunteers (blue) and female volunteers (pink) who said that they were very or quite satisfied with the characteristics and efficacy of the lotions used. Most subjects (≥ 50%) expressed good satisfaction.*
*”A liposome-based formulation containing equol, dihomo-γ-linolenic acid and propionyl-L-carnitine to prevent and treat hair loss: A prospective investigation” G.Brotzu, A.M.Fadda, M.L.Manca, T.Manca, F.Marongiu, M.Campisi, F.Consolaro; Dermatologic Therapy, Ott.2018

img

Table 1. Results of the study. The asterisks indicate the significance of the statistical tests compared to the baseline condition, before treatment. *, p p<0.05; **, p p<0.01; ***, p p<0.001; ****, p p<0.0001*
*”A liposome-based formulation containing equol, dihomo-γ-linolenic acid and propionyl-L-carnitine to prevent and treat hair loss: A prospective investigation” G.Brotzu, A.M.Fadda, M.L.Manca, T.Manca, F.Marongiu, M.Campisi, F.Consolaro; Dermatologic Therapy, Ott.2018

All the latest from our blog
Read all the articles
English